Sales of Gaucher disease therapeutics will rise gradually from $875
million in 2014 to $1.16 billion by 2024 across the seven major markets (7MM)
of the UK, Italy, Spain, France, Germany, the US and Israel, at a Compound
Annual Growth Rate (CAGR) of 2.9%, according to new research.
The company’s latest report states that while a lack of drugs in
late-stage development will limit the expansion of the Gaucher disease
treatment market by 2024, growth will be driven by an increase in the number of
diagnosed prevalent Gaucher disease cases, meaning the treated population is
rising.
According to Senior Analyst covering Cardiovascular and Metabolic
Disorders, comments: “This increase can be attributed to continued efforts by
Genzyme and Shire to raise awareness of such a rare condition as Gaucher
disease.
“It can also be credited to new screening programs, such as the
lysosomal storage disorder new-born screening program introduced in the state
of Missouri.”
The analyst adds that despite the anticipated improvements in
diagnosis and treatment, a large portion of the Gaucher disease population will
go untreated over the forecast period, due to continued late diagnosis and
misdiagnosis of Gaucher disease as a result of its heterogeneous
manifestations.
Interestingly, the country that will experience the most substantial
market growth is Israel, which will see an impressive CAGR of 8.4% over the
forecast period, despite holding a more modest market share than the rest of
the 7MM.
Senior Analyst explains: “The substantially faster growth in the
Israeli Gaucher disease market compared with the US and the European markets
will be driven by the greater increase in the diagnostic rate due to a high
level of disease awareness in Israel among both physicians and the general
public.
“An increase in the treatment rate in Israel, which is currently much
lower compared with the other regions in the 7MM, will also contribute to the
growth of Israeli Gaucher disease drug sales.”
The report also states that the market dominance of the US is set to
continue during the forecast period, with the country commanding approximately
56.2% of the Gaucher disease treatment space in the 7MM by 2024.
OpportunityAnalyzer: Gaucher Disease - Opportunity Analysis and
Forecast to 2024 report provides an overview of Gaucher disease and its
treatment space across the seven major countries of the UK, Italy, Spain,
France, Germany the US and Israel, including annualized market data from 2014
and forecast to 2024.
This report was built using data and information sourced from
proprietary databases, primary and secondary research, and in-house analysis
conducted by Publisher’s team of industry experts.
For
more information Visit at: http://mrr.cm/Joi
Find all Healthcare Reports
at: http://www.marketresearchreports.com/healthcare
No comments:
Post a Comment
Note: only a member of this blog may post a comment.